公开(公告)号：US20040018235A1

公开(公告)日：2004-01-29

申请号：US10461432

申请日：2003-06-16

申请人： KOWA CO., LTD ,  Nissan Chemical Industries Limited

发明人： Yoshio Tanizawa ,  Tatsuharu Shimokawa ,  Hirotada Ogawa ,  Mayumi Watanabe ,  Chihiro Ohashi ,  Hiroyuki Kawashima ,  Yasuo Shinoda ,  Toshio Inagi

IPC分类号： A61K031/366 ,  A61K009/22 ,  A61K031/225

CPC分类号： A61K31/47 ,  A61K9/2081 ,  A61K9/209 ,  A61K9/5026 ,  A61K9/5036 ,  A61K9/5078 ,  A61K9/5084

摘要： The present invention is drawn to a pharmaceutical composition characterized by containing a composition (A) which contains pitavastatin, a salt thereof, or an ester thereof and which initiates release thereof at least in the stomach, and an enteric composition (B) which contains pitavastatin, a salt thereof, or an ester thereof. By use of the controlled release pharmaceutical composition of the present invention, the blood level of pitavastatin can be maintained at an appropriate level immediately after administration over a long period of time. Thus, highly safety and effective treatment of hypercholesterolemia can be performed.

摘要翻译： 本发明涉及一种药物组合物，其特征在于含有含有匹伐他汀，其盐或其酯，至少在胃中释放的组合物（A）和含有匹伐他汀的肠溶组合物（B） ，其盐或其酯。 通过使用本发明的控释药物组合物，可以长时间给药后立即维持匹伐他汀的血药浓度。 因此，可以进行高胆固醇血症的高度安全和有效的治疗。

公开(公告)号：US20040019122A1

公开(公告)日：2004-01-29

申请号：US10414008

申请日：2003-04-16

申请人： KOWA CO., LTD.

发明人： Niichiro Takano ,  Hiroyuki Kawashima ,  Yasuo Shinoda ,  Toshio Inagi

IPC分类号： C08L001/00

CPC分类号： A61K9/1652 ,  A61K9/146 ,  A61K9/1641 ,  A61K9/2077 ,  A61K31/50

摘要： The invention provides a solid dispersion composition containing 2-benzyl-5-(4-chlorophenyl)-6-null4-(methylthio)phenylnull-2H-pyridazin-3-one, hydroxypropylmethyl cellulose, and polyoxyethylene polyoxypropylene glycol. The solid dispersion composition of the present invention exhibits the excellent dissolvability of 2-benzyl-5-(4-chlorophenyl)-6-null4-(methylthio)phenylnull-2H-pyridazin-3-one in water, and enables this compound to be constant sequentially and thereby improve absorbability in blood.